HLB Pharmaceutical said on Feb. 2 that operating profit last year fell 28.4% to 1.05499 billion won.
Sales for the same period rose 49.9% to 205.58173 billion won. Compared with 2022, they nearly doubled.
The company said that the performance of Shinhwa Advance, acquired last year, was reflected in the consolidation financial statements, and that the consumer healthcare division turned a profit two years after its launch, helping build a sales base.
※ This article has been translated by AI. Share your feedback here.